

Additive interaction of mid- to late-life depression and cerebrovascular disease on the risk of dementia: A nationwide population-based cohort study

Yoo Jin Jang

Samsung Medical Center Department of Psychiatry

Cinoo Kang

Seoul National University Graduate School of Public Health

Woojae Myung

Seoul National University Bundang Hospital Department of Neuropsychiatry

Shinn-Won Lim

Samsung Advanced Institute for Health Sciences and Technology

Young Kyung Moon

Samsung Medical Center Department of Psychiatry

Ho Kim

Seoul National University Institute of Health and Environment

Doh Kwan Kim (✉ paulkim@skku.edu)

Sungkyunkwan University School of Medicine <https://orcid.org/0000-0002-2302-6153>

Research

Keywords: dementia, depression, cerebrovascular disease, Alzheimer's disease, additive interaction, risk factors, nationwide population, cohort study

Posted Date: October 1st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-34212/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on March 16th, 2021. See the published version at <https://doi.org/10.1186/s13195-021-00800-z>.

Abstract

Background: Dementia is a progressive neurocognitive disease with a substantial social burden. No apparent breakthroughs in treatment options have emerged so far; thus, disease prevention is essential for at-risk populations. Depression and cerebrovascular disease (CVD) are independent risk factors for dementia, but no studies have examined their interaction effect on dementia risk. This study aimed to identify the association of depression and CVD with the risk of dementia and evaluate whether dementia risk among patients with comorbid depression and CVD is higher than the sum of the individual risk due to each condition.

Methods: A population-based cohort study was conducted to analyze the Korean National Health Insurance Service-National Sample Cohort data of all individuals over 50 years of age. Individuals who had not been diagnosed with dementia at baseline were included and followed up from January 1, 2005 to December 31, 2013. A time-varying Cox proportional hazard regression model adjusted for potential confounding factors was used for the analysis. The interaction between depression and CVD was estimated based on attributable proportion (AP), relative excess risk due to interaction (RERI), synergy index (SI), and multiplicative-scale interaction.

Results: A total of 242,237 participants were included in the analytical sample, of which 12,735 (5.3%) developed dementia. Compared to that for participants without depression or CVD, the adjusted hazard ratio for the incidence of dementia for those with depression alone was 2.35 (95% confidence interval [CI]: 2.21-2.49), CVD alone was 3.25 (95% CI: 3.11-3.39), and comorbid depression and CVD was 5.02 (95% CI: 4.66-5.42). The additive interaction between depression and CVD was statistically significant (AP: 0.08, 95% CI: 0.01-0.16; RERI: 0.42, 95% CI: 0.03-0.82; SI: 1.12, 95% CI: 1.01-1.24). The multiplicative interaction was significant too, but effect was negative (0.66, 95% CI: 0.60-0.73).

Conclusions: In this population-based nationwide cohort with long-term follow-up, depression and CVD were associated with an increased risk of dementia, and their coexistence additively increased dementia risk more than the sum of the individual risks.

Background

Dementia is a neurodegenerative disease characterized by progressive cognitive decline. It precludes patients from carrying out daily life activities independently and often has devastating effects on the lives of patients and their caregivers. Although the prevalence and disease burden of dementia are increasing [1], there have been no apparent breakthroughs in terms of treatment options to date. Therefore, identifying at-risk populations and providing tailored care is essential for cost-effective public health management [2].

Depression has been suggested as a risk factor for dementia. According to recent meta-analyses of several epidemiological studies [3, 4], late-life depression is associated with increased dementia risk. Furthermore, some researchers have proposed a correlation between vascular damage and the transition

from depression to dementia. In a recent large-scale retrospective study that included 35,791 individuals with 13 years of follow-up, depression was found to have an exceptionally significant effect on dementia in individuals with incident stroke [5]. Armstrong *et al.* [6] conducted a longitudinal study and reported that late-life depression partially mediates the association between cardiovascular disease and cognitive decline. Vascular dysfunction by itself is known to cause cognitive decline through changes in the blood supply [7, 8], inflammation [9-11], changes involving the immune system [12], as well as brain parenchymal damage [13-15]. In particular, cerebrovascular disease (CVD), which is typically characterized by cerebral ischemia and hemorrhage, is a widely known independent risk factor for dementia [13, 15-19]. Depression and CVD both cause hypothalamic-pituitary-adrenal (HPA) axis dysregulation [20], chronic inflammation [21], and endothelial dysfunction [22], and aggravate each other. Depressive patients are at higher risk of stroke-related morbidity and mortality [23], and the reverse is true as well [24]. The association between depression and microvascular dysfunction has also been described in a recent systemic review and meta-analysis [25]. Although these influential risk factors are known to be correlated, the interaction effect of depression and CVD on dementia risk has not yet been well established. Therefore, whether concomitant depression and CVD increase the risk of dementia more than the sum of individual effects remains undetermined.

In the current study, we sought to evaluate the association of depression and CVD with subsequent dementia using a nationwide population-based cohort. We also aimed to investigate whether the interaction between the two conditions is additively associated with increased dementia risk. Since the epidemiology of depression, CVD, and dementia is dependent upon age and sex, we intended to determine the effect modification by age or sex.

Methods

Participants

We used the nationwide population-based South Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC) database [26], which contains the data of approximately 1 million people (2.2% of the total Korean population) and uses systematic stratified random sampling with proportional allocation within each stratum (age, sex, insurance eligibility status, and income level). As the National Health Insurance (NHI) program requires mandatory health insurance for all Korean citizens, the database is representative of the South Korean population. All insurance claims are catalogued in this system, and the medical information in the database is provided exclusively by healthcare providers. Every NHI member older than 40 years is eligible for biennial cardiovascular health panel screening and cancer screening for free or at a minimal cost depending on income [27]. Prior studies have validated the NHIS-NSC data for some chronic diseases, including stroke and dementia [28-31]. Yet, the validation of the International Classification of Diseases, 10th revision (ICD-10) codes for depression diagnosis has not been evaluated [32].

Of the 1,044,097 individuals who were enrolled in the cohort during the baseline period (January 1st, 2002 to December 31st, 2004), we included 244,920 individuals over the age of 50 years and then excluded 2,683 who had or received a dementia diagnosis during this period (Fig. 1). We followed up the participants from the index date (January 1st, 2005) until December 31st, 2013, or until the date of dementia onset within that period, defined as the follow-up period. Patient death and the end of the follow-up were treated as censoring events in the analyses. During the follow-up period of up to 9 years, individuals were classified into the following four groups based on their depression or CVD diagnosis: individuals with neither depression nor CVD, those with depression alone, those with CVD alone, and those with both depression and CVD.

The final analyses included a total of 242,237 participants. The institutional review board of the Samsung Medical Center, Seoul, South Korea approved this study. All data were anonymized and kept confidential, and thus, the need for obtaining participant informed consent was waived.

Exposure variables: depression and CVD

Depression was defined as the assignment of an ICD-10 code for depressive disorder (F32 or F33) and the documented administration of antidepressant medication (Additional file 1: Table S1) from the first day of depression diagnosis during the follow-up period as previously described [33-35]. CVD was defined as the assignment of an ICD-10 code for CVD (I60-69) as a primary diagnosis and two or more hospital visits during the follow-up period [35]. Unlike the medications used for depression or dementia, CVD medications are not exclusive to the disease. Therefore, we defined CVD based on the ICD codes and multiple hospital visits regardless of the medications prescribed.

Outcome of interest: dementia

The primary outcome was overall survival free of dementia. We defined dementia as the assignment of an ICD-10 code for dementia (F00-03, G30-31) and the documented administration of anti-dementia medication (donepezil, rivastigmine, galantamine, or memantine) during the follow-up period [33, 36, 37]. As mentioned above, we excluded all cases with a dementia diagnosis during the baseline period to focus on incident cases of dementia. Dementia subtype was set as the secondary outcome and was defined based on the initial ICD-10 code assigned on the first day of dementia diagnosis: F00 and G30 for Alzheimer's disease (AD); F01 for vascular dementia (VD); and F02-03 and G31 for other dementias (non-AD or non-VD).

Covariates

All analyses were adjusted for potential confounding variables—age, sex, residential area, income level, and comorbidities—during the baseline period from 2002 to 2004. With regard to residential area, the capital city of South Korea and the surrounding metropolitan cities (Seoul, Incheon, Gyeonggi-do) were designated as the 'capital region'; all other regions were designated as 'non-capital regions.' Income levels were classified as low (up to the 30th percentile), middle (30th to 70th percentile), and high (70th to 100th

percentile). The ICD-10 codes from the Charlson comorbidity index, which is used widely to adjust for the effects of comorbidities [38], were used. We defined the comorbidities based on the ICD-10 codes for each disease (Additional file 1: Table S2) and two or more hospital visits during the baseline period.

Interaction measurements

We assessed additive- and multiplicative-scale interaction measures to examine the interaction effect of depression and CVD on dementia onset. In terms of the additive interaction, we derived the attributable proportion due to interaction [AP; equation (1)], relative excess risk due to interaction [RERI; equation (2)], and synergy index [SI; equation (3)]. The AP is the proportion of the risk due to the interaction in the doubly exposed group (null hypothesis: AP=0). When RERI is positive, it indicates increased risk due to the additive interaction (null hypothesis: RERI=0). SI can be interpreted as the ratio of an increased risk due to both exposures to the sum of individual increased risks (null hypothesis: SI=1). These were used to assess whether the risk due to having both diseases is greater than the sum of the risks due to each condition [39, 40].

$$AP_{Interaction} = \frac{HR_{Depression \& CVD} - HR_{Depression} - HR_{CVD} + 1}{HR_{Depression \& CVD}} \quad (1)$$

$$RERI_{Interaction} = HR_{Depression \& CVD} - HR_{Depression} - HR_{CVD} + 1 \quad (2)$$

$$SI_{Interaction} = \frac{HR_{Depression \& CVD} - 1}{HR_{Depression} + HR_{CVD} - 2} \quad (3)$$

The multiplicative-scale interaction [equation (4)] has been widely used to examine interaction effects by identifying whether the risk due to having both diseases is greater than the product of the risks due to each disease alone (null hypothesis: multiplicative interaction=1) [39, 40].

$$Mult_{Interaction} = \frac{HR_{Depression \& CVD}}{HR_{Depression} \times HR_{CVD}} \quad (4)$$

In equations (1-4), $HR_{Depression \& CVD}$ represents the hazard ratio (HR) for those who have both depression and CVD. $HR_{Depression}$ and HR_{CVD} represent the HR for those who have depression or CVD alone, respectively, compared with individuals who have neither of the conditions.

Statistical analysis

We used Cox proportional hazards regression models to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of depression, CVD, or comorbid depression and CVD for dementia

incidence. As the cohort design can cause an immortal-time bias, we used a time-varying Cox regression model to prevent time-related biases [41, 42]. An unadjusted time-varying Cox regression analysis was performed (Model 1), followed by a demographic characteristics-adjusted (Model 2; adjusted for age, sex, residential area, and income level) and a comorbidity-adjusted (Model 3; adjusted for myocardial infarction, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, connective tissue disorder, peptic ulcer, mild liver disease, uncomplicated diabetes, complicated diabetes, hemiplegia, moderate or severe renal diseases, non-metastatic solid cancer, moderate or severe liver diseases, and metastatic solid cancer in addition to the demographic characteristics in Model 2) analysis. The proportional hazards assumption was graphically tested and verified using the Schoenfeld residual method; no variables violated the assumption.

First, we used a log-rank test and evaluated independent associations of depression and CVD with subsequent dementia using aHRs and 95% CIs in two separate regression models. In this analysis, exposure of interest (depression or CVD) was treated as a time-varying variable, and the other comorbid illnesses were regarded as time-fixed confounders to be adjusted. Next, we examined the interaction effect of the two exposure diseases by calculating the additive (AP, RERI, and SI) and multiplicative interaction. We verified the significance of the interaction term and then stratified each subgroup based on age or sex. We then conducted a subgroup analysis using a fully-adjusted Cox regression model (Model 3; demographic characteristics and comorbidities adjusted) in which dementia subtypes (AD, VD, and non-AD or non-VD) were accounted into the outcome variables.

We also carried out sensitivity analyses to ensure the robustness of the results. First, lagged-time analysis was conducted because depression that occurs shortly before dementia onset can be a prodrome of dementia [43]. We classified individuals who were newly diagnosed with depression during the lagged-time period into the 'no depression' group. Second, we repeated the analysis using ICD-10 code disease definitions only. As the strict operational definitions of depression, CVD, and dementia can lead to selection bias, we applied mitigated definitions regardless of medication prescriptions or the number of hospital visits. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC/USA).

Results

Participant characteristics and incidence of dementia

Participant characteristics are presented in Table 1. A total of 242,237 participants were included in the analyses (77,587 [68.0%] aged over 65 years at baseline; 131,712 [54.4%] women; 140,415 [58.0%] from non-capital regions). A total of 7,006 (2.9%) participants had histories of depression during the baseline period, and 9,680 (4.0%) participants had a history of CVD during the same period. The demographic characteristics of the study participants and the diseases from the Charlson comorbidity index were set as covariates (Table 1). During the follow-up period, 12,735 (5.3%) participants were newly diagnosed with dementia (AD, 9,729 [76.4%]; VD, 1,306 [10.3%]; non-AD or non-VD, 1,700 [13.3%]; Additional file 1:

Table S3). There were significant differences between the groups in terms of age, sex, income level, and comorbidities (p-value < 0.05).

When the patients were classified into the four categories as shown in Fig. 1, the number of patients with newly diagnosed dementia was 7,525 (4.0 %) in the reference group ($N = 190,255$; 78.5%), 1,336 (6.8%) in the depression alone group ($N = 19,692$; 8.1%), 3,099 (11.6%) in the CVD alone group ($N = 26,798$; 11.1%), and 775 (14.1%) in the comorbid depression and CVD group ($N = 5,492$; 2.3%).

Independent associations of depression and CVD with increased dementia risk

We found significant associations of depression and CVD with the risk of dementia (Additional file 1: Fig. S1). In the time-varying Cox proportional hazard model analysis, depression was associated with a 122% increased risk of dementia (aHR: 2.22, 95% CI: 2.12-2.33; Table 2, Fig. 2A) after adjusting for age, sex, residential area, income level, and comorbid chronic diseases, compared to participants without depression. The lagged-time analyses showed that the effect of depression was significant even after considering depression that occurred within the lagged-time period up to two years as a prodrome of dementia (Additional file 1: Table S4). The analyses with CVD showed that it was associated with a higher hazard for dementia onset (aHR: 3.12, 95% CI: 3.00-3.25; Table 2, Fig. 2B). Significant effect modifications were observed according to age and sex subgroups in both the analyses for depression and CVD patients (all p-values for the interactions between diseases and age or sex were <0.0001). The association between depression and subsequent dementia was especially high in those under the age of 65 and men, and the same was observed for CVD (Table 2).

Interaction effect of depression and CVD on dementia risk

Compared to the no depression or CVD group, the depression alone group (aHR: 2.35, 95% CI: 2.21-2.49), CVD alone group (aHR: 3.25, 95% CI: 3.11-3.39), and comorbid depression and CVD group (aHR: 5.02, 95% CI: 4.66-5.42) were significantly associated with an increased risk of dementia (Table 3). All indices of the additive interaction were statistically significant with positive values (AP: 0.08, 95% CI: 0.01-0.16; RERI: 0.42, 95% CI: 0.03-0.82; SI: 1.12, 95% CI: 1.01-1.24; Table 3 and Fig. 2C). When participants were classified according to their dementia subtypes, significant additive interaction between depression and CVD was found with AD (AP: 0.09, 95% CI: 0.00-0.18; RERI: 0.41, 95% CI: -0.01-0.83; SI: 1.13, 95% CI: 1.00-1.28; Table 3). VD or other dementia were not associated with the interaction effect of the two diseases. The effect modification by age was statistically insignificant. On the other hand, the interaction effect between depression and CVD changed with sex and was significant only in women (AP: 0.12, 95% CI: 0.03-0.21; RERI: 0.53, 95% CI: 0.11-0.95; SI: 1.18, 95% CI: 1.04-1.34; Table 3). The multiplicative interaction was significant in every analysis, but the effect was negative (Table 3). The sensitivity analysis using disease definitions based on the ICD-10 codes further supported the results (Additional file 1: Table S5).

Discussion

In this analysis of a nationwide population-based cohort of 242,237 participants aged over 50 years, depression and CVD were independently associated with a more than double the risk of dementia. After adjusting for demographic factors and comorbidities, we found a positive additive interaction between depression and CVD on dementia risk, and this interaction effect was significant only in women. In the analyses with dementia subtypes, the interaction effect was associated with AD.

Our results reinforce the claim that individuals with depression or CVD are more vulnerable to subsequent dementia. We replicated prior findings with a large population-based sample and also tested the generalizability of our results. In this study, the effect of depression on incident dementia was found to be more significant in individuals below the age of 65 years and men. Our finding that participants with depression that appeared in middle-age are more vulnerable to subsequent dementia contradicts those of some studies [44, 45] that have reported that late-life depression is more strongly associated with dementia than mid-life depression. However, a few researchers have argued that early-onset (before the age of 65 years) depression may be a long-term risk factor for dementia [46]. Whether the effect of depression on dementia risk differs according to the age of onset or the duration of morbidity is controversial and needs further investigation. The effect modifications of sex on depression as a risk factor for AD reported by previous studies have also been inconsistent [47]. According to a recent systematic review [48], these discrepant findings may be accounted for by methodological differences, such as those related to the recruitment method (clinic-based or population-based), follow-up duration, and measure of depression used. The current results provide evidence that depression among men in a community-based population is more strongly associated with increased dementia risk than among women.

Individuals with CVD, especially VD, were more likely to be diagnosed with dementia, with more than three times the risk, which is in line with previous literature [49]. Moreover, CVDs in men and younger age groups were more strongly associated with increased dementia risk. This is consistent with previous studies which reported that post-stroke dementia is more prevalent in men [50]. In large-scale population-based cohort studies on the association of cardiovascular risk [51] and blood pressure pattern [52] with cognitive function, researchers have consistently reported that mid-life vascular disease has a more substantial effect on dementia onset. Our findings highlight the importance of midlife as a critical period for later cognitive function.

We found that both additive and multiplicative interactions of depression and CVD on dementia risk were statistically significant. However, they showed the opposite effect. This is a commonly observed phenomenon with respect to positive additive interaction [39]. Although the negative multiplicative interaction effect may be partially explained by the operational definition of medication use or multiple hospital visits (possible therapeutic or protective effect), VanderWeele and Knol [53] reported that additive interaction, rather than multiplicative interaction, is more suitable and important to be assessed as a relevant public health measure. They also presented a similar case to our results (that is, simultaneously significant positive additive interaction and negative multiplicative interaction). They suggested that a multiplicative-scale interaction sometimes indicates the wrong subgroup for intervention or treatment. It

is calculated based on the risk ratio, which depends on the different baseline subgroup risks; therefore, in terms of biological plausibility and from the public health perspective, a positive additive interaction seems more reasonable than a negative multiplicative interaction in the context of our study [54].

The positive additive interaction between depression and CVD on dementia risk remained statistically significant after adjusting for covariates. Although we cannot clarify the underlying biological mechanisms based on this study, one possible explanation is that each illness exacerbates the other condition through biological and psychosocial changes. Stroke limits patients' activities of daily living and impairs their social and cognitive functions. It frequently gives rise to a depressed mood as a psychosocial reaction [12]. Vascular damage in specific brain regions related to mood regulation could make patients susceptible to depressive disorders [55]. Besides, depression might affect patient health behaviors and make them vulnerable to CVD through HPA axis dysregulation or a chronic inflammatory state [22]. Another explanation for the additive interaction between depression and CVD is related to AD pathology. In the analysis of dementia subtypes, the interaction between depression and CVD was only associated with AD. Although it requires cautious interpretation, we hypothesize that the concurrence of vascular dysfunction from CVD and AD pathology triggered by depression initiates and aggravates clinically significant cognitive decline. In a recent clinical study on CVD and AD pathology with 218 participants, CVD was not associated with the rate of the beta-amyloid accumulation, but the comorbidity of CVD and amyloid plaques accumulation was associated with cognitive decline [56]. Chronic stress and hypercortisolemia can induce beta-amyloid accumulation, hyperphosphorylation of Tau proteins, and neurotoxicity [57]. A prior study reported that depressed patients have higher beta-amyloid aggregation levels than healthy individuals [58]. The additive interaction of depression and CVD on the dementia risk in our study was more remarkable in women, who are known to be at risk of AD [1]. This was in line with an animal study that reported that chronic stress resulted in increased amyloid plaques in the female mouse hippocampus only, although there were no cerebral cortical changes in either male or female mice [59]. Given the menopausal age, the sex effect seems to be explained little by the role of estrogen alone. The biological mechanism of additive interaction should be investigated further.

Our findings indicate that individuals with depression or CVD require thorough preventive approaches to avoid another illness. Although treating depressive disorder might not change the course of a patient's cognitive decline [45], managing vascular risk factors and preventing CVD in individuals with depression would reduce the incidence of dementia as well as the personal and socioeconomic disease burdens. Women are known to have a higher risk of depression; therefore, targeting this at-risk population can also help dementia prevention policies work more effectively.

Limitations

This study has some limitations. The NHIS-NSC database contains health insurance claims data and not diagnostic data [20]. Accordingly, it is possible that the disease diagnosis data used in this research are inaccurate, which may have resulted in misclassification of patients who did not seek treatment as healthy controls. We set up strict operational definitions using multiple hospital visits or drug prescription

data in addition to the ICD-10 codes to validate the diagnoses. However, these criteria also cause a selection bias, so we would have accidentally excluded “real” patients who did not visit hospitals or missed their diagnosis due to minimal symptoms. Additionally, the characteristics of the cohort can influence the results. Since the database did not include non-insurance benefits data [26], we missed out depressed patients who underwent non-pharmacological treatments, such as cognitive-behavioral therapy. Notwithstanding, individuals who take medication for depression or cognitive decline without being diagnosed can be considered rare, because it is not recommended to prescribe medication without a relevant ICD-10 diagnosis in Korea. Moreover, the prevalence of each disease in our sample was similar to that from other Korean registries [60-62], and the HRs for depression [3, 24, 45, 63] and CVD [15, 16, 64, 65] were also similar to those previously reported. The identification of dementia etiologies without biopsies or autopsies is complicated; therefore, we had no choice but to determine the dementia subtypes according to the initial codes of the main diagnoses for our analyses. Unfortunately, this method cannot differentiate between clinically noteworthy dementia etiologies that are not specified in a single ICD-10 code, such as “mixed dementia.” Another limitation is that our results were based on individuals who benefited from the universal healthcare system of South Korea. Consequently, our results have limited generalizability for other ethnicities and healthcare systems. Additionally, the consideration of possible confounding factors could be considered insufficient. Health-related behaviors, such as drinking and smoking, are known to affect depression, CVD, and dementia. They depend on age and sex; therefore, our findings with regard to effect modification by age and sex should be interpreted with caution.

Conclusions

This nationwide, population-based cohort study demonstrates that both depression and CVD, as well as their interaction, are associated with an increased dementia risk. To the best of our knowledge, this is the first study to examine the coexistence effect of depression and CVD on subsequent dementia risk, and we found positive additive interaction between depression and CVD on the increased risk of dementia. Our results suggest that individuals with depression or CVD need interventions to prevent other conditions and that further investigation on the relevance of AD is required.

Abbreviations

AD: Alzheimer’s disease; aHR: adjusted hazard ratio; AP: attributable proportion; CI: confidence interval; CVD: cerebrovascular disease; HPA: hypothalamic-pituitary-adrenal; HR: hazard ratio; ICD-10: International Classification of Diseases, 10th revision; NHI: National Health Insurance; NHIS-NSC: National Health Insurance Service-National Sample Cohort; RERI: relative excess risk due to interaction; SI: synergy index; VD: vascular dementia

Declarations

Ethics approval and consent to participate

The ethics review board of the Samsung Medical Center approved our access to the anonymized data sets used for these analyses (IRB no. 2019-03-105). All data were de-identified and kept confidential, and therefore, participants' informed consent was not required.

Consent for publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available from the Korean National Health Insurance Service (NHIS), but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission from the NHIS.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by grants from Sungkyunkwan University (Sungkyun Research Fund 2017 to DKK) and the National Research Foundation (NRF) funded by the Korean government (MSIT, 2020R1A2C2101276 to DKK), Republic of Korea.

Authors' contributions

DKK and HK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. YJJ and CK conceived and designed the study, acquired and analyzed the data, interpreted the study findings, and drafted the manuscript. YJJ, CK, WM, SWL, YKM, DKK, and HK conceived and designed the study, defined exclusion criteria and exposure, outcome, and covariate categories, and interpreted the study findings. WM, SWL, DKK, and HK supervised and directed the conduct of the study, and critically reviewed the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. YJJ and CK contributed equally to this work as co-first authors. DKK (paulkim@skku.edu) and HK (hokim@snu.ac.kr) contributed equally to this work and should be considered as co-corresponding authors.

Acknowledgements

We would like to thank Editage (www.editage.co.kr) for English language editing.

References

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2016;12:459-509.
2. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. *Drugs*. 2012;72:789-802.
3. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF, 3rd. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. *Br J Psychiatry*. 2013;202:329-35.
4. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. *Arch Gen Psychiatry*. 2006;63:530-8.
5. Kohler S, Buntinx F, Palmer K, van den Akker M. Depression, vascular factors, and risk of dementia in primary care: a retrospective cohort study. *J Am Geriatr Soc*. 2015;63:692-8.
6. Armstrong NM, Carlson MC, Schrack J, Xue QL, Carnethon MR, Rosano C, et al. Late-Life Depressive Symptoms as Partial Mediators in the Associations between Subclinical Cardiovascular Disease with Onset of Mild Cognitive Impairment and Dementia. *Am J Geriatr Psychiatry*. 2018;26:559-68.
7. Hughes TM, Craft S, Lopez OL. Review of 'the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease'. *Neurodegener Dis Manag*. 2015;5:121-35.
8. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci*. 2017;18:419-34.
9. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. *Ann N Y Acad Sci*. 2010;1207:155-62.
10. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. *J Cereb Blood Flow Metab*. 2016;36:172-86.
11. Villa RF, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. *Pharmacol Ther*. 2018;184:131-44.
12. Mijajlovic MD, Pavlovic A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, et al. Post-stroke dementia - a comprehensive review. *BMC Med*. 2017;15:11.
13. Cao L, Tan L, Wang HF, Jiang T, Zhu XC, Yu JT. Cerebral Microinfarcts and Dementia: A Systematic Review and Metaanalysis. *Curr Alzheimer Res*. 2017;14:802-8.
14. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol*. 2017;134:171-86.
15. Liu W, Wong A, Law AC, Mok VC. Cerebrovascular disease, amyloid plaques, and dementia. *Stroke*. 2015;46:1402-7.
16. Corraini P, Henderson VW, Ording AG, Pedersen L, Horvath-Puho E, Sorensen HT. Long-Term Risk of Dementia Among Survivors of Ischemic or Hemorrhagic Stroke. *Stroke*. 2017;48:180-6.
17. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american

- heart association/american stroke association. *Stroke*. 2011;42:2672-713.
18. Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. *Alzheimers Dement*. 2013;9:76-92.
 19. Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer's disease. *Acta Neuropathol*. 2016;131:645-58.
 20. Du X, Pang TY. Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? *Front Psychiatry*. 2015;6:32.
 21. Halaris A. Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease. *Curr Top Behav Neurosci*. 2017;31:45-70.
 22. Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. *J Clin Neurosci*. 2018;47:1-5.
 23. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. *Jama*. 2011;306:1241-9.
 24. Aizenstein HJ, Baskys A, Boldrini M, Butters MA, Diniz BS, Jaiswal MK, et al. Vascular depression consensus report - a critical update. *BMC Med*. 2016;14:161.
 25. van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA, Schram MT. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2017;74:729-39.
 26. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. *Int J Epidemiol*. 2017;46:e15.
 27. Shin DW, Cho B, Guallar E. Korean National Health Insurance Database. *JAMA Internal Medicine*. 2016;176:138-.
 28. Wu CS, Kuo CJ, Su CH, Wang SH, Dai HJ. Using text mining to extract depressive symptoms and to validate the diagnosis of major depressive disorder from electronic health records. *J Affect Disord*. 2020;260:617-23.
 29. Lee CK, Ha HJ, Oh SJ, Kim JW, Lee JK, Kim HS, et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. *J Gastroenterol Hepatol*. 2020;35:760-8.
 30. Lyu HG, Haider AH, Landman AB, Raut CP. The opportunities and shortcomings of using big data and national databases for sarcoma research. *Cancer*. 2019;125:2926-34.
 31. Kim JH, Yoo KB, Lee Y. Development and validation of the Korea Dementia Comorbidity Index (KDCl): A nationwide population-based cohort study from 2002 to 2013. *Arch Gerontol Geriatr*. 2017;72:195-200.
 32. Kang JI, Sung NY, Park SJ, Lee CG, Lee BO. The epidemiology of psychiatric disorders among women with breast cancer in South Korea: analysis of national registry data. *Psychooncology*. 2014;23:35-9.
 33. Katon W, Pedersen HS, Ribe AR, Fenger-Gron M, Davydow D, Waldorff FB, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. *JAMA*

- Psychiatry. 2015;72:612-9.
34. Doktorchik C, Patten S, Eastwood C, Peng M, Chen G, Beck CA, et al. Validation of a case definition for depression in administrative data against primary chart data as a reference standard. *BMC Psychiatry*. 2019;19:9.
 35. McPheeters ML, Sathe NA, Jerome RN, Carnahan RM. Methods for systematic reviews of administrative database studies capturing health outcomes of interest. *Vaccine*. 2013;31 Suppl 10:K2-6.
 36. Kim CT, Myung W, Lewis M, Lee H, Kim SE, Lee K, et al. Exposure to General Anesthesia and Risk of Dementia: A Nationwide Population-Based Cohort Study. *J Alzheimers Dis*. 2018;63:395-405.
 37. Jaakkimainen RL, Bronskill SE, Tierney MC, Herrmann N, Green D, Young J, et al. Identification of Physician-Diagnosed Alzheimer's Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians' Electronic Medical Records. *J Alzheimers Dis*. 2016;54:337-49.
 38. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43:1130-9.
 39. VanderWeele T, Knol M. A Tutorial on Interaction. *Epidemiologic Methods*. 2014;3.
 40. Li R, Chambless L. Test for additive interaction in proportional hazards models. *Ann Epidemiol*. 2007;17:227-36.
 41. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *Bmj*. 2010;340:b5087.
 42. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. *Crit Care Med*. 2009;37:2939-45.
 43. Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? *Maturitas*. 2014;79:184-90.
 44. Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimaki M, et al. Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study. *JAMA Psychiatry*. 2017;74:712-8.
 45. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a modifiable factor to decrease the risk of dementia. *Transl Psychiatry*. 2017;7:e1117.
 46. Kessing LV. Depression and the risk for dementia. *Curr Opin Psychiatry*. 2012;25:457-61.
 47. Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. *Dialogues Clin Neurosci*. 2016;18:437-46.
 48. Underwood EA, Davidson HP, Azam AB, Tierney MC. Sex Differences in Depression as a Risk Factor for Alzheimer's Disease: A Systematic Review. *Innov Aging*. 2019;3:igz015.
 49. Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. *Nat Rev Neurol*. 2017;13:148-59.

50. Pendlebury ST, Rothwell PM. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. *Lancet Neurol.* 2019;18:248-58.
51. Tarraf W, Kaplan R, Daviglius M, Gallo LC, Schneiderman N, Penedo FJ, et al. Cardiovascular Risk and Cognitive Function in Middle-Aged and Older Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *J Alzheimers Dis.* 2020;73:103-16.
52. Walker KA, Sharrett AR, Wu A, Schneider ALC, Albert M, Lutsey PL, et al. Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. *Jama.* 2019;322:535-45.
53. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. *Eur J Epidemiol.* 2011;26:433-8.
54. Szklo M. The evaluation of epidemiologic evidence for policy-making. *Am J Epidemiol.* 2001;154:S13-7.
55. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. *Am J Psychiatry.* 2016;173:221-31.
56. Yassi N, Hilal S, Xia Y, Lim YY, Watson R, Kuijf H, et al. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-beta on Alzheimer's Disease. *J Alzheimers Dis.* 2020;73:897-907.
57. Sotiropoulos I, Silva JM, Gomes P, Sousa N, Almeida OFX. Stress and the Etiopathogenesis of Alzheimer's Disease and Depression. *Adv Exp Med Biol.* 2019;1184:241-57.
58. Yasuda S, Baba H, Maeshima H, Shimano T, Inoue M, Ichikawa T, et al. Serum levels and mutual correlations of amyloid beta in patients with depression. *Geriatr Gerontol Int.* 2020;20:125-9.
59. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. *Mol Brain.* 2010;3:34.
60. Shin C, Kim Y, Park S, Yoon S, Ko Y-H, Kim Y-K, et al. Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014. *J Korean Med Sci.* 2017;32:1861-9.
61. Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, et al. Executive Summary of Stroke Statistics in Korea 2018: A Report from the Epidemiology Research Council of the Korean Stroke Society. *J Stroke.* 2019;21:42-59.
62. Kim YJ, Han JW, So YS, Seo JY, Kim KY, Kim KW. Prevalence and Trends of Dementia in Korea: A Systematic Review and Meta-Analysis. *jkms.* 2014;29:903-12.
63. Byers AL, Yaffe K. Depression and risk of developing dementia. *Nat Rev Neurol.* 2011;7:323-31.
64. Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, et al. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. *Ageing Res Rev.* 2017;34:77-87.
65. Goldwasser EL, Acharya NK, Sarkar A, Godsey G, Nagele RG. Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease. *J Alzheimers Dis.* 2016;54:445-56.

Tables

Table 1 Descriptive characteristics of the study population

Study Population	With Dementia		Without Dementia	
	N	%	N	%
TOTAL	242,237	100.0	12,735	100.0
Age				
50 to 64 years	164,650	68.0	3,345	26.3
Above 64 years	77,587	32.0	9,390	73.7
Sex				
Men	110,525	45.6	3,982	31.3
Women	131,712	54.4	8,753	68.7
Residential area^a				
Capital region	101,822	42.0	4,403	34.6
Non-capital region	140,415	58.0	8,332	65.4
Income level^b				
Low	65,730	27.1	3,948	31.0
Middle	80,753	33.3	3,683	28.9
High	95,754	39.5	5,104	40.1
Comorbidities				
Myocardial infarction	2,332	1.0	156	1.2
Congestive heart failure	8,904	3.7	814	6.4
Peripheral vascular disease	6,661	2.8	575	4.5
Chronic pulmonary disease	47,871	19.8	3,232	25.4
Connective tissue disorder	11,761	4.9	881	6.9
Peptic ulcer	50,849	21.0	2,984	23.4
Mild liver disease	22,914	9.5	1,022	8.0
Uncomplicated diabetes	29,720	12.3	2,209	17.4
Complicated diabetes ^c	11,717	4.8	933	7.3
Hemiplegia	1,533	0.6	151	1.2
Moderate or severe renal diseases	1,476	0.6	96	0.8
Non-metastatic solid cancer ^d	9,382	3.9	435	3.4
Moderate or severe liver diseases	754	0.3	17	0.1
Metastatic solid cancer	2,805	1.2	51	0.4
Depression	7,006	2.9	652	5.1
Cerebrovascular disease	9,680	4.0	1,007	7.91

^aIndividuals who resided in the capital city of South Korea and surrounding metropolitan cities (Seoul, Incheon, Gyeonggi-do) were classified as belonging to the “capital region” and the others to the “non-capital region”

^bIncome levels were divided into three groups: low (up to the 30th percentile), middle (30th to 70th percentile), and high (70th to 100th percentile) income.

^cDiabetes complicated with retinopathy, neuropathy, or renal disease

^dNon-metastatic solid cancer, including leukemia, lymphoma, and multiple myeloma

Table 2 Cox regression analysis for independent associations between depression/CVD and dementia

No Depression	Depression	No CVD	CVD	
Total population	217,053 (89.6%)	25,184 (10.4%)	209,947 (86.7%)	32,290 (13.3%)
Dementia events	10,624 (4.9%)	2,111 (8.4%)	8,861 (4.2%)	3,874 (12.0%)
Person-years	1,777,860	210,499	1,734,836	253,523
Incidence (events/1,000 person-years)	5.98	10.03	5.11	15.28
Log-rank test (p-value)	< 0.0001		< 0.0001	
Unadjusted HR in Model 1 (95% CI)	1 [Reference]	2.40 (2.29-2.51)	1 [Reference]	4.36 (4.20-4.53)
aHR in Model 2 (95% CI) ^a	1 [Reference]	2.35 (2.24-2.46)	1 [Reference]	3.26 (3.14-3.39)
aHR in Model 3 (95% CI) ^b	1 [Reference]	2.22 (2.12-2.33)	1 [Reference]	3.12 (3.00-3.25)
Age 50 to 64 years	147,019 (89.3%)	17,631 (10.7%)	147,069 (89.3%)	17,851 (10.7%)
Dementia events	2,591 (1.8%)	754 (4.3%)	2,150 (1.5%)	1,195 (6.8%)
Person-years	1,271,789	152,534	1,276,238	148,084
Incidence (events/1,000 person-years)	2.04	4.94	1.68	8.07
Log-rank test (p-value)	< 0.0001		< 0.0001	
Unadjusted HR in Model 1 (95% CI)	1 [Reference]	3.43 (3.16-3.72)	1 [Reference]	6.82 (6.35-7.32)
aHR in Model 2 (95% CI) ^a	1 [Reference]	3.24 (2.99-3.52)	1 [Reference]	6.84 (6.37-7.34)
aHR in Model 3 (95% CI) ^b	1 [Reference]	3.11 (2.86-3.37)	1 [Reference]	6.54 (6.09-7.03)
Age above 64 years	70,034 (90.3%)	7,553 (9.7%)	62,878 (81.0%)	14,709 (19.0%)
Dementia events	8,033 (11.5%)	1,357 (18.0%)	6,711 (10.7%)	2,679 (18.2%)
Person-years	506,071	57,965	458,597	105,439
Incidence (events/1,000 person-years)	15.87	23.41	14.63	25.41
Log-rank test (p-value)	< 0.0001		< 0.0001	
Unadjusted HR in Model 1 (95% CI)	1 [Reference]	2.06 (1.95-2.18)	1 [Reference]	2.50 (2.39-2.62)
aHR in Model 2 (95% CI) ^a	1 [Reference]	2.04 (1.93-2.16)	1 [Reference]	2.55 (2.43-2.66)
aHR in Model 3 (95% CI) ^b	1 [Reference]	1.92 (1.81-2.04)	1 [Reference]	2.44 (2.33-2.56)
Men	102,043 (92.3%)	8,482 (7.7%)	95,637 (86.5%)	14,888 (13.5%)
Dementia events	3,388 (3.3%)	594 (7.0%)	2,531 (2.7%)	1,451 (9.6%)
Person-years	831,452	69,492	784,992	115,952
Incidence (events/1,000 person-years)	4.07	8.55	3.22	12.51
Log-rank test (p-value)	< 0.0001		< 0.0001	
Unadjusted HR in Model 1 (95% CI)	1 [Reference]	3.13 (2.87-3.42)	1 [Reference]	5.69 (5.33-6.07)
aHR in Model 2 (95% CI) ^a	1 [Reference]	2.83 (2.60-3.09)	1 [Reference]	4.15 (3.88-4.42)
aHR in Model 3 (95% CI) ^b	1 [Reference]	2.69 (2.46-2.93)	1 [Reference]	3.99 (3.74-4.26)
Women	115,010 (87.3%)	16,702 (12.7%)	114,310 (86.8%)	17,402 (13.2%)
Dementia events	7,236 (6.3%)	1,517 (9.1%)	6,330 (5.5%)	2,423 (13.9%)
Person-years	946,408	141,007	949,844	137,571
Incidence (events/1,000 person-years)	7.65	10.76	6.66	17.61
Log-rank test (p-value)	< 0.0001		< 0.0001	
Unadjusted HR in Model 1 (95% CI)	1 [Reference]	1.97 (1.87-2.09)	1 [Reference]	3.84 (3.67-4.03)
aHR in Model 2 (95% CI) ^a	1 [Reference]	2.19 (2.07-2.32)	1 [Reference]	2.89 (2.76-3.03)
aHR in Model 3 (95% CI) ^b	1 [Reference]	2.07 (1.96-2.19)	1 [Reference]	2.77 (2.64-2.91)

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; CVD, cerebrovascular disease; HR, hazard ratio

^aAdjusted for demographic characteristics (age, sex, residential area, and income level)

^bAdjusted for demographic characteristics (age, sex, residential area, and income level), other exposure diseases, and 14 comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, connective tissue disorder, peptic ulcer, mild liver disease, uncomplicated diabetes, complicated diabetes, hemiplegia, moderate or severe renal diseases, non-metastatic solid cancer, moderate or severe liver diseases, and metastatic solid cancer)

Table 3 Interaction effect of depression and CVD on the risk of dementia onset

	Risk of Dementia by Exposure, HR (95% CI)				Additive Interaction (95% CI)			Multiplicative Interaction ^a (95% CI)
	No Depression or CVD	Depression	CVD	Depression and CVD	AP ^a	RERI ^a	SI ^a	
Model 1^b	1 [Reference]	2.41 (2.27-2.55)	4.51 (4.32-4.70)	6.54 (6.08-7.05)	0.10 (0.02-0.17)	0.63 (0.13-1.13)	1.13 (1.03-1.24)	0.60 (0.55-0.67)
Model 2^c	1 [Reference]	2.39 (2.26-2.54)	3.33 (3.19-3.47)	5.16 (4.79-5.56)	0.09 (0.01-0.16)	0.44 (0.04-0.84)	1.12 (1.01-1.24)	0.65 (0.59-0.71)
Model 3^d	1 [Reference]	2.35 (2.21-2.49)	3.25 (3.11-3.39)	5.02 (4.66-5.42)	0.08 (0.01-0.16)	0.42 (0.03-0.82)	1.12 (1.01-1.24)	0.66 (0.60-0.73)
Dementia Subtype^e								
AD	1 [Reference]	2.36 (2.21-2.52)	2.77 (2.63-2.91)	4.54 (4.15-4.95)	0.09 (0.00-0.18)	0.41 (-0.01-0.83)	1.13 (1.00-1.28)	0.69 (0.62-0.78)
VD	1 [Reference]	2.13 (1.68-2.70)	9.75 (8.64-11.02)	11.98 (9.74-14.75)	0.09 (-0.14-0.32)	1.1 (-1.29-3.49)	1.11 (0.89-1.39)	0.58 (0.42-0.78)
Non-AD or Non-VD ^f	1 [Reference]	2.37 (2.02-2.78)	2.97 (2.64-3.35)	4.55 (3.68-5.62)	0.05 (-0.18-0.28)	0.21 (-0.80-1.22)	1.06 (0.80-1.42)	0.65 (0.49-0.85)
Age^g								
50 to 64 years	1 [Reference]	3.46 (3.12-3.83)	6.93 (6.38-7.53)	10.10 (8.85-11.53)	0.07 (-0.07-0.21)	0.72 (-0.61-2.05)	1.09 (0.94-1.26)	0.42 (0.36-0.50)
Above 64 years	1 [Reference]	2.01 (1.87-2.16)	2.53 (2.41-2.66)	3.83 (3.50-4.21)	0.08 (-0.02-0.18)	0.29 (-0.08-0.67)	1.12 (0.97-1.28)	0.75 (0.67-0.85)
Sex^g								
Men	1 [Reference]	3.16 (2.82-3.54)	4.31 (4.01-4.64)	6.71 (5.85-7.69)	0.04 (-0.12-0.19)	0.24 (-0.71-1.19)	1.04 (0.88-1.23)	0.75 (0.67-0.85)
Women	1 [Reference]	2.11 (1.97-2.26)	2.82 (2.67-2.97)	4.46 (4.07-4.88)	0.12 (0.03-0.21)	0.53 (0.11-0.95)	1.18 (1.04-1.34)	0.69 (0.62-0.78)

Abbreviations: AD, Alzheimer's disease; AP, attributable proportion due to interaction; CI, confidence interval; CVD, cerebrovascular disease; HR, hazard ratio; RERI, relative excess risk due to interaction; SI, synergy index; VD, vascular dementia

^aNull hypothesis for each interaction is AP = 0, RERI=0, SI=1, and multiplicative interaction=1

^bUnadjusted model

^cAdjusted for demographic characteristics (age, sex, residential area, and income level)

^dAdjusted for demographic characteristics (age, sex, residential area, and income level) and 14 comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, connective tissue disorder, peptic ulcer, mild liver disease, uncomplicated diabetes, complicated diabetes, hemiplegia, moderate or severe renal diseases, non-metastatic solid cancer, moderate or severe liver diseases, and metastatic solid cancer)

^eSubgroup analysis for dementia subtype was based on Model 3 (adjusted for demographic characteristics and 14 comorbidities) and conducted separately by considering the other dementia subtypes as a competing risk

^fIncludes dementia in other diseases classified elsewhere (F02), unspecified dementia (F03), other degenerative diseases of the nervous system, and not elsewhere classified (G31)

^gSubgroup analyses for age and sex were based on Model 3 (adjusted for demographic characteristics and 14 comorbidities). Age or sex was not considered as a covariate in each subgroup analysis

Figures




Figure 1

Study population flow diagram




Figure 2

Survival curves for dementia onset according to exposure diseases

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [DEPCVDDemAdditionalfileclean200914M.docx](#)
- [FigureS1A.tif](#)
- [FigureS1B.tif](#)
- [FigureS1C.tif](#)